NCT06366490View on ClinicalTrials.gov

Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy in Recurrent Epithelial Ovarian Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 30, 2026

Primary Completion Date

June 30, 2026

Study Completion Date

December 30, 2026

Conditions
Ovarian Cancer
Interventions
BIOLOGICAL

Innocell Autologous Cellular Immunotherapy

Innocell Autologous Cellular Immunotherapy

Sponsors

Lead Sponsor

PhotonPharma, Inc.
All Listed Sponsors
lead

PhotonPharma, Inc.

INDUSTRY